EUVIMEDEUVIMED entdecken
Crossref

The Potential of ESCO2 as a Prognostic and Immunotherapeutic Marker of Pan-Cancer and Its Role in Anti-PD-1 Treatment of Bladder Cancer

Wei Guo, Shuo Zhao, Keqiang Yan, Yidong Fan, Jikai Liu

Oncology · 2024

DOI: 10.1159/000542188 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology, 2024. Verfasst von Wei Guo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Qilu Hospital of Shandong University, Jinan, China. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Biomarkers, Tumor, Acetyltransferases, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Establishment of sister chromatid cohesion N-acetyltransferase 2 (ESCO2), a member of the EFO2 family, is implicated in the pathogenesis and progression of various cancers. However, there has been limited comprehensive pan-cancer analysis conducted on ESCO2 thus far.

Methods

Publicly available databases, such as the UCSC Xena database, were utilized to examine differential expression patterns across various cancer types. In addition, variations in expression levels were investigated across distinct clinical stages. Univariate Cox regression and Kaplan-Meier survival analyses were conducted to evaluate the impact on overall survival (OS), disease-specific survival (DSS), disease-free interval (DFI), and progression-free interval (PFI) at the pan-cancer level. The correlation between ESCO2 expression and immune cell infiltration was examined to gain insight into the tumor microenvironment (TME) in different cancers. The results of the bioinformatic analysis were validated using immunotherapy clinical trials and pathological specimens. CCK-8 and Transwell assay experiments were performed to investigate the biological function of ESCO2.

Results

ESCO2 expression was found to be upregulated in most cancers, with a correlation to TNM stages. Prognostic analysis indicated that overexpression of ESCO2 was associated with poor prognosis in various cancers. Furthermore, the correlation between ESCO2 expression and immune cell infiltration suggested its potential as a predictor for immunotherapy efficacy. Notably, ESCO2 expression showed positive associations with immunoinhibitor, immunostimulator, major histocompatibility complex (MHC) molecule, chemokine receptor, tumor mutation burden (TMB), and microsatellite instability (MSI) levels in bladder cancer (BLCA). The validation cohort for immunotherapy corroborated these findings and substantiated that ESCO2 could function as an autonomous prognostic biomarker and a promising target for cancer treatment via immunotherapy. In addition, in vitro experiments confirmed the role of ESCO2 in influencing the proliferation, invasion, and migration of BLCA cells.

Conclusion

ESCO2 participates in regulating the immune infiltration and affecting the prognosis of patients in many cancers, especially in BLCA. ESCO2 may serve as a prognostic and immunotherapy biomarker in future treatment of human cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsBiomarkers, TumorAcetyltransferasesImmune Checkpoint InhibitorsHumansPrognosisTumor MicroenvironmentImmunotherapyFemaleProgrammed Cell Death 1 ReceptorMaleGene Expression Regulation, NeoplasticKaplan-Meier Estimate

Stichwörter der Autor:innen

BioinformaticsBladder cancerESCO2ImmunotherapyPan-cancer analysis

Substanzen

Biomarkers, TumorAcetyltransferasesImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorPDCD1 protein, human

Autor:innen und Institutionen

  • Department of Urology, Qilu Hospital of Shandong University, Jinan, China.

Zitieren

APA

Guo, W., Zhao, S., Yan, K., Fan, Y., & Liu, J. (2024). The Potential of ESCO2 as a Prognostic and Immunotherapeutic Marker of Pan-Cancer and Its Role in Anti-PD-1 Treatment of Bladder Cancer. Oncology. https://doi.org/10.1159/000542188

Vancouver

Guo W, Zhao S, Yan K, Fan Y, Liu J. The Potential of ESCO2 as a Prognostic and Immunotherapeutic Marker of Pan-Cancer and Its Role in Anti-PD-1 Treatment of Bladder Cancer. Oncology. 2024. doi:10.1159/000542188

BibTeX
@article{Guo2024,
  author = {Guo, Wei and Zhao, Shuo and Yan, Keqiang and Fan, Yidong and Liu, Jikai},
  title = {The Potential of ESCO2 as a Prognostic and Immunotherapeutic Marker of Pan-Cancer and Its Role in Anti-PD-1 Treatment of Bladder Cancer},
  journal = {Oncology},
  year = {2024},
  doi = {10.1159/000542188}
}
Kostenlos starten →